KR920703102A - Polypeptides that selectively react with antibodies against human immunodeficiency virus (HUMAN IMMUNODEFICIENCY VIRUS) and vaccines containing them (VACCINES) - Google Patents

Polypeptides that selectively react with antibodies against human immunodeficiency virus (HUMAN IMMUNODEFICIENCY VIRUS) and vaccines containing them (VACCINES)

Info

Publication number
KR920703102A
KR920703102A KR1019920701393A KR920701393A KR920703102A KR 920703102 A KR920703102 A KR 920703102A KR 1019920701393 A KR1019920701393 A KR 1019920701393A KR 920701393 A KR920701393 A KR 920701393A KR 920703102 A KR920703102 A KR 920703102A
Authority
KR
South Korea
Prior art keywords
hiv
amino acid
acid sequence
protein
antibody
Prior art date
Application number
KR1019920701393A
Other languages
Korean (ko)
Inventor
아비그도르 샤퍼만
Original Assignee
아비그도르 샤퍼만
원본미기재
유니박스 바이오로직스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23786972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR920703102(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아비그도르 샤퍼만, 원본미기재, 유니박스 바이오로직스, 인코포레이티드 filed Critical 아비그도르 샤퍼만
Priority claimed from PCT/US1990/007210 external-priority patent/WO1991009872A1/en
Publication of KR920703102A publication Critical patent/KR920703102A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/221—Retrovirus related, or human immunodeficiency virus related, or simian immunodeficiency virus related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

내용 없음No content

Description

인간 면역결핍 바이러스(HUMAN IMMUNODEFICIENCY VIRUS)에 대한 항체와 선택적으로 반응하는 폴리펩타이드 및 그를 함유하는 백신(VACCINES)Polypeptides that selectively react with antibodies against human immunodeficiency virus (HUMAN IMMUNODEFICIENCY VIRUS) and vaccines containing them (VACCINES)

[도면의 간단한 설명][Brief Description of Drawings]

제1도는 HIV88(제1a도), HlV500(제1b도), HIV582(제1c도) 및 HlV647(제1d)을 위한 올리고뉴클레오티드 서열 코딩(coding) 을 도시한 것이다.Figure 1 depicts oligonucleotide sequence coding for HIV88 (Figure 1a), HlV500 (Figure 1b), HIV582 (Figure 1c) and HlV647 (Figure 1d).

제2도는 SIV88(제2a도), SIV500 (제2b도), SIV582(제2c도) 및 SIV647(제2d도)에 대해 코딩하는 올리고뉴클레오티드 서열을 도시한 것이다.Figure 2 depicts the oligonucleotide sequences encoding for SIV88 (Figure 2a), SIV500 (Figure 2b), SIV582 (Figure 2c) and SIV647 (Figure 2d).

제1도 및 제2도에서, 각각의 폴리펩타이드를 위한 인코드(encode)된 아미노산이 제한 엔도뉴클레아제를 위한 인식부위인 것 처럼 도시되었고 각 부위가 위에 표시되었는데 HIV-1 게놈(genome)으로 부터 올리고뉴클레오티드를 얻는데 사용될 수 있다.In Figures 1 and 2, the encoded amino acids for each polypeptide are shown as being recognition sites for restriction endonucleases and each site is indicated above the HIV-1 genome. It can be used to obtain oligonucleotides from.

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (18)

아미노산 서열과 폴리펩타이드 서열이 용융단백질에 뼈대를 포함하도록 NVTENFNMWKN, KAKRRVVQREKRAVG, ERYLKDQQLLGIWGCSGKLIC 와 EESQNQQEKNEQELLELDKWA로 이루어진 군으로 부터 선택된 아미노산 서열 및 비 HIV 폴리펩타이드 서열로 이루어진 용융단백질을 포함하는데 상기 용융 단백질이 HIV 양성 혈청과 반응함을 특징으로 하는 용융단백질.The amino acid sequence and polypeptide sequence comprise a fusion protein consisting of an amino acid sequence and a non-HIV polypeptide sequence selected from the group consisting of NVTENFNMWKN, KAKRRVVQREKRAVG, ERYLKDQQLLGIWGCSGKLIC and EESQNQQEKNEQELLELDKWA so that the amino acid sequence and the polypeptide sequence contain a skeleton in the molten protein. Melt protein, characterized in that the reaction. 제1항에 있어서, 상기 아미노산 서열이 상기 플리펩타이드 서열의 N말단에 펩타이드 결합으로 결합됨을 특징으로 하는 용융단백질.According to claim 1, wherein the amino acid sequence is a fusion protein, characterized in that coupled to the N-terminal of the polypeptide peptide peptide bond. 제2항에 있어서, 상기 폴리펩타이드 서열이 β-갈락토시다제의 서열을 포함하는 것을 특징으로 하는 용융단백질.3. The molten protein of claim 2, wherein said polypeptide sequence comprises a sequence of β-galactosidase. NVTENFNMWKN, KKAKRRVVQREKRAVG, ERYLKDQQLLGIWGCSGKLIC와 EESQNQQEKNEQELLELDKWA로 이루어진 그룹으로 부터 선택된 아미노산 서열을 포함하는 폴리펩타이드를 발현하는 것을 특징으로 하는 자기복제세포.A self-replicating cell characterized by expressing a polypeptide comprising an amino acid sequence selected from the group consisting of NVTENFNMWKN, KKAKRRVVQREKRAVG, ERYLKDQQLLGIWGCSGKLIC and EESQNQQEKNEQELLELDKWA. (A) 아미노산 서열이 기질의 표면과 접촉하는 항체에 가까이 할 수 있도록 아미노산 서열 ERYLKDQQLLGIWGCSGKLIC과 비 HIV 폴리펩타이드 서열을 포함하는 용융단백질을 고체기질에 고정시키고, (B) 상기 기질의 표면과 접촉하도록 샘플을 위치시키고 (C) HIV 특이항체의 결합을 위한 상기 표면을 모니터하는 단계를 포함하는 샘플에서 항 HIV 항체의 존재를 검출하기 위한 진단학적 평가법.(A) A molten protein comprising the amino acid sequence ERYLKDQQLLGIWGCSGKLIC and a non-HIV polypeptide sequence is immobilized on a solid substrate such that the amino acid sequence is close to the antibody in contact with the surface of the substrate, and (B) the sample is brought into contact with the surface of the substrate. And (C) monitoring the surface for the binding of HIV specific antibodies. Diagnostic assay for detecting the presence of anti-HIV antibodies in a sample. 제5항에 있어서, (C) 단계가 통상의 호울 바이러스 웨스턴 블롯평가법을 이용하여 테스트할때 HIV 음성을 시험하는 샘플에서 항 HIV 항체의 존재를 검출하는 것을 포함하는 진단학적 평가법.The diagnostic assay of claim 5, wherein step (C) comprises detecting the presence of anti-HIV antibodies in a sample that tests for HIV negative when tested using a conventional Hollow virus western blot assay. (A) 아미노산 서열 ERYLKDQQLIGlWGCSGKLIC과 효소의 아미노산 서열을 포함하는 용융단백질을 제공하고, (B) 액체내에서 용융단백질과 샘풀을 조합시키며, (C) 효소활성의 변조를 위한 조합을 모니터 하는 단계를 포함하는 샘풀에서 항 HIV 항체의 존재를 검출하기 위한 진단학적 평가법.(A) providing a molten protein comprising the amino acid sequence ERYLKDQQLIGlWGCSGKLIC and the amino acid sequence of the enzyme, (B) combining the molten protein and the sample in a liquid, and (C) monitoring the combination for modulation of enzymatic activity A diagnostic assay for detecting the presence of anti-HIV antibodies in a sample. 제1항에 의한 용융단백질과 무균의 약제학적으로 수용가능한 캐리어를 포함하는 것을 특징으로 하는 백신.A vaccine comprising the molten protein of claim 1 and a sterile pharmaceutically acceptable carrier. 제8항에 의한 면역자극적인 양의 백신을 피검자에게 투여하는 단계를 포함하는 것을 특징으로 하는 면역요법.An immunotherapy comprising administering an immunostimulatory amount of the vaccine of claim 8 to a subject. 제9항에 있어서, 백신이 투여될때 피검자가 이미 HIV-1에 감염된 것을 특징으로 하는 면역요법.10. The immunotherapy of claim 9, wherein the subject is already infected with HIV-1 when the vaccine is administered. HIV-1에 대하여 향하는 항체를 함유하는 초면역 글로블린이 생성되도록 제8항에 의한 백신으로 플라즈마 공급체를 면역시키는 단계를 포함하는 것을 특징으로 하는 HIV 감염에 대한 면역치료적 제제를 제조하는 방법.A method for preparing an immunotherapeutic agent for HIV infection, comprising immunizing a plasma supply with a vaccine according to claim 8 to produce a superimmune globulin containing an antibody directed against HIV-1. 제11항에 의해 제조된 면역자극적인 약의 초면역 글로블린을 피검자에게 투여하는 단계를 포함하는 것을 특징으로 하는 면역치료방법.A method of immunotherapy comprising administering to a subject a superimmune globulin of an immunostimulatory drug prepared by the subject of claim 11. 제1항에 의한 용융단백질에 대하여 향하는 항체를 HIV-1에 감염된 피검자에게 투여하는 단계를 포함하는데 상기 항체가 면역독소에 콘쥬게이트되는 것을 특징으로 하는 면역치료 방법.A method for immunotherapy comprising administering to a subject infected with HIV-1 an antibody directed against the molten protein of claim 1, wherein the antibody is conjugated to an immunotoxin. 면역독소에 콘쥬게이트된 제1항에 의한 용융단백질을 포함하는 것을 특징으로 하는 면역독소 콘쥬게이트.An immunotoxin conjugate comprising a fusion protein according to claim 1 conjugated to an immunotoxin. 기본적으로 제1항에 의한 용융단백질을 결합하는 항체로 이루어진 것을 특징으로 하는 조성물.Basically, a composition comprising an antibody binding to the molten protein according to claim 1. 제15항에 있어서, 상기 조성물이 모노클로날 항체 조성물인 것을 특징으로 하는 조성물.16. The composition of claim 15, wherein said composition is a monoclonal antibody composition. 제15항에 있어서, 상기 항체는 HIV-1에 감염된 인간 피검자로 부터 생물학적 샘플을 제공하는 단계를 포함하는 공정에 의해서 얻어지지 않는 것을 특징으로 하는 조성물.The composition of claim 15, wherein said antibody is not obtained by a process comprising providing a biological sample from a human subject infected with HIV-1. ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920701393A 1989-12-13 1990-12-13 Polypeptides that selectively react with antibodies against human immunodeficiency virus (HUMAN IMMUNODEFICIENCY VIRUS) and vaccines containing them (VACCINES) KR920703102A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/450,150 US6248574B1 (en) 1989-12-13 1989-12-13 Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
US450,150 1989-12-13
PCT/US1990/007210 WO1991009872A1 (en) 1989-12-13 1990-12-13 Hiv-1 env fragment fusion protein

Publications (1)

Publication Number Publication Date
KR920703102A true KR920703102A (en) 1992-12-17

Family

ID=23786972

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920701393A KR920703102A (en) 1989-12-13 1990-12-13 Polypeptides that selectively react with antibodies against human immunodeficiency virus (HUMAN IMMUNODEFICIENCY VIRUS) and vaccines containing them (VACCINES)

Country Status (7)

Country Link
US (1) US6248574B1 (en)
EP (1) EP0509006A1 (en)
JP (1) JPH05503926A (en)
KR (1) KR920703102A (en)
AU (1) AU653926B2 (en)
CA (1) CA2071858A1 (en)
IL (1) IL96647A0 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US20070202127A1 (en) * 1993-06-07 2007-08-30 Duke University Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
US7358334B1 (en) 2003-11-14 2008-04-15 Jay W Chaplin B cell-targeted toxins for humoral immune response reduction and methods of use thereof
AU2018366480C1 (en) * 2017-11-17 2024-02-01 Grifols Diagnostic Solutions Inc. Novel mammalian expressed human immunodeficiency virus envelope protein antigens

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0201540B2 (en) 1984-10-18 2001-10-31 Institut Pasteur Envelope antigens of lymphadenopathy associated virus and their applications
ATE116006T1 (en) 1985-04-29 1995-01-15 Genetic Systems Corp SYNTHETIC ANTIGENS FOR DETECTING AIDS.
US4745055A (en) * 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
JP2702911B2 (en) 1985-09-11 1998-01-26 ユナイテツド・バイオメデイカル・インコ−ポレ−テツド Synthetic peptide, and method for detecting AIDS and pre-AIDS using the same
EP0227169B1 (en) 1985-12-17 1993-03-17 Akzo N.V. Immunochemical reagent
US4772547A (en) 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US4736896A (en) 1986-02-18 1988-04-12 Hollymatic Corporation Automatic-feed grinder and meat grinding method
AU7234387A (en) 1986-03-24 1987-10-20 Ortho Pharmaceutical Corporation Synthetic htlv-iii peptides, compositions and uses thereof
US4879212A (en) 1986-04-02 1989-11-07 United Biomedical Inc. Peptide composition and method for the detection of antibodies to HTLV-III
IE63109B1 (en) 1986-06-23 1995-03-22 Genetic Systems Corp Human monoclonal antibody to lymphadenopathy-associated virus
AU7786387A (en) 1986-07-21 1988-02-10 Southwest Foundation For Biomedical Research Composition of matter and method of immunizing against viral causative agents of aids and arc
DE3855947T2 (en) * 1987-01-16 1997-12-11 Pasteur Institut Peptides with the immunological properties of HIV-2
US4918166A (en) * 1987-04-10 1990-04-17 Oxford Gene Systems Limited Particulate hybrid HIV antigens
JP2777160B2 (en) 1987-04-16 1998-07-16 ジョンソン アンド ジョンソン STLV-3-related polypeptides, diagnostic systems and assays
DE3727137A1 (en) 1987-08-14 1989-02-23 Behringwerke Ag PRODUCTION OF ANTIGENS OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 AND THEIR USE AS A DIAGNOSTIC AGENT AND THERAPEUTIC
JP2902658B2 (en) 1987-08-21 1999-06-07 スクリップス クリニック アンド リサーチ ファウンデーション HIV-1-related polypeptides, diagnostic systems and assay methods
SE8704185L (en) 1987-10-28 1989-04-29 Ferring Ab NEW PEPTIDES, ARTIFICIAL ANTIGENS AND IMMUNO ANALYSIS TEST RATES
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
WO1989009393A1 (en) 1988-03-24 1989-10-05 Igen, Inc. Luminescent chimeric proteins
AU608413B2 (en) 1988-03-30 1991-03-28 Abbott Laboratories Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein
EP0362909A3 (en) 1988-08-26 1990-11-14 Akzo N.V. Synthetic polypeptides immunochemically reactive with hiv-antibodies

Also Published As

Publication number Publication date
IL96647A0 (en) 1991-09-16
AU7033391A (en) 1991-07-24
WO1991009872A2 (en) 1991-07-11
AU653926B2 (en) 1994-10-20
EP0509006A1 (en) 1992-10-21
US6248574B1 (en) 2001-06-19
CA2071858A1 (en) 1991-06-14
WO1991009872A3 (en) 1992-04-02
JPH05503926A (en) 1993-06-24

Similar Documents

Publication Publication Date Title
US5013548A (en) Production of antibodies to HIV
Gnann Jr et al. Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus
US5019387A (en) Production of antibodies to HIV
AU693098B2 (en) Tandem synthetic HIV-1 peptides
KR910002374B1 (en) Synthetic antigens for the detection of aids-relate disease
US7070787B2 (en) Method of inducing the production of antibodies to HIV
EP0245362A4 (en) Synthetic peptides and use for diagnosis and vaccination for aids and arc.
KR890701742A (en) Heterologous Peptide Particle Immunogen
EP0292454A2 (en) Synthetic peptide antigen for the detection of HIV-2 infection
KR970010925B1 (en) Hcv peptide - antigens and a method of testing for the hepatitis c virus(hcv)
IL127595A (en) Polypeptides capable of forming antigen binding structures with specificity for the rhesus d antigens, the dna encoding them and the process for their preparation and use
JP2003525014A5 (en)
KR920703102A (en) Polypeptides that selectively react with antibodies against human immunodeficiency virus (HUMAN IMMUNODEFICIENCY VIRUS) and vaccines containing them (VACCINES)
DE69231705T2 (en) Gag-Env fusion antigen from HIV
RU2337922C9 (en) ISOLATED POLYPEPTIDES BASED ON NEUTRALISING OF PROTEIN p17 OF HIV VIRUS, USED AS VACCINES, AND NEUTRALISING ANTI-p17-ANTIBODIES, SPECIFICALLY RECOGNISING SAID NEUTRALISING
DE3879881D1 (en) RECOMBINANT HIV-2 POLYPEPTIDE.
EP0582243B2 (en) HCV peptide antigens and a method of testing for the hepatitis C virus (HCV)
WO2001016182A3 (en) POLYPEPTIDES THAT BIND HIV gp120 AND RELATED NUCLEIC ACIDS, ANTIBODIES, COMPOSITIONS, AND METHODS OF USE
US5688914A (en) Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus
US5310876A (en) Expression of HIV1 and HIV2 polypeptides and their use
EP0605433B1 (en) Immunoassay for the simultaneous detection of hiv-1, hiv-2, htlv-i and htlv-ii antibodies
CN101146827A (en) HIV TAT-CD4 hybried molecules and methods of use thereof
IE904083A1 (en) Diagnostic proteins to test for more than one antibody
Page et al. Studies on the immunogenicity of Chinese hamster ovary cell-derived recombinant gp120 (HIV-1IIIB)
Krust et al. Characterization of a monoclonal antibody specific for the HIV-1 precursor glycoprotein

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid